SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
PARIS, Jan. 29, 2016 -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2016.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
| -- 2015 Full-Year Results | March 7, 2016 | |||
| -- Shareholders’ AGM | April 12, 2016 | |||
| -- 2016 Half-Year results | October 14, 2016 |
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
